This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
SANO is a randomized parallel-group treatment trial evaluating active surveillance in the management of oesophageal cancer following neoadjuvant chemoradiotherapy. The registry lists overall survival as the primary endpoint.
| Feature | SANO |
|---|---|
| ClinicalTrials.gov identifier | NCT05953181 |
| Condition | Esophageal Cancer; Active Surveillance; Neoadjuvant Chemoradiotherapy; Surgical Oncology |
| Design | Randomized parallel-group study |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | Erasmus Medical Center |
| Status | Active, not recruiting |
2. Clinical Question
The clinical question addressed by SANO is whether an active surveillance strategy can be evaluated against surgical management pathways after neoadjuvant chemoradiotherapy for patients with oesophageal cancer.
Population
Patients with oesophageal cancer enrolled in a randomized treatment study involving neoadjuvant chemoradiotherapy and active surveillance.
Intervention
Active surveillance (procedure).
Comparator
The registry identifies a randomized two-arm comparison but does not provide additional comparator details in the record.
Primary question
The primary statistical question concerns overall survival between randomized strategies.
3. Trial Design
4. Primary Endpoint
| Endpoint | Definition / Time Frame |
|---|---|
| Overall survival | The interval between the moment of achieving cCR (i.e. the moment the patient will start the intervention) and death or last follow-up, with a minimal follow-up of two years after reaching cCR. |
5. Planned Analysis
The ClinicalTrials.gov record identifies overall survival as the primary endpoint but does not report posted statistical analyses or outcome estimates.
Overall survival is a time-to-event endpoint. A typical statistical analysis for this endpoint would evaluate the distribution of survival times using methods such as Kaplan-Meier estimation, compare randomized groups using a survival comparison test, and estimate relative treatment effects using a survival regression model such as the Cox proportional-hazards model.
The survival function describes the probability that a patient remains alive beyond a specified time point. Patients who are alive at their last follow-up contribute censored information rather than being treated as events.
6. Statistical Methodology
Randomization
Randomization is the foundation of the comparative design. By assigning participants to study strategies through a random process, treatment groups can be compared without relying only on observed baseline characteristics.
Overall survival analysis
Overall survival analysis accounts for different lengths of follow-up among participants. The endpoint includes both observed deaths and censored observations for patients whose final follow-up occurs before death.
Censoring
Censoring occurs when the exact event time is not observed during the study period. Correct handling of censoring allows available follow-up information to contribute to the survival analysis.
Hazard ratios
A hazard ratio is commonly used in randomized survival studies to summarize the relative instantaneous event rate between groups over follow-up. It is not equivalent to a difference in survival probability or a direct measure of individual benefit.
7. Statistical Methods Explained
Why is overall survival analysed as a time-to-event endpoint?
Patients enter the study at different times and may have different follow-up durations. Time-to-event methods allow all available survival information to contribute to the analysis.
Why is censoring important?
A participant who has not experienced death by the end of available follow-up still provides information. Treating these observations correctly prevents loss of useful follow-up data.
What does a hazard ratio measure?
A hazard ratio compares estimated event rates between groups over time. It does not directly state the percentage of patients who survive or the difference in median survival.
Why is randomization important?
Randomization helps balance known and unknown prognostic factors between treatment groups, strengthening causal interpretation of differences in outcomes.
Why is follow-up duration important for overall survival?
Overall survival events accumulate over time. Longer follow-up can provide more information about the durability of differences between randomized strategies.
8. Limitations and Interpretation Issues
- No posted outcome estimates: The registry does not report survival estimates, effect estimates, confidence intervals, or p-values.
- Endpoint maturity: Overall survival requires sufficient follow-up and event accumulation for reliable estimation.
- Trial design context: Interpretation depends on the randomized comparison, analysis population, and prespecified statistical plan.
- Censoring assumptions: Survival analyses rely on appropriate handling of censored observations.
- Generalizability: Applicability depends on the characteristics of patients enrolled in the randomized study.
9. Why This Trial Matters Statistically
SANO is a useful statistical example because it illustrates how randomized oncology trials evaluate alternative treatment strategies using time-to-event outcomes.
| Concept | How it appears in SANO |
|---|---|
| Randomization | Randomized allocation between two treatment strategies |
| Parallel design | Two-arm comparative trial structure |
| Primary endpoint | Overall survival |
| Time-to-event methods | Appropriate framework for survival outcomes |
| Censoring | Required consideration in survival follow-up |
| Clinical decision strategies | Comparison of active surveillance and surgical oncology approaches |
10. Sources
- ClinicalTrials.gov: NCT05953181.
Continue through the Clinical Biostats knowledge graph
Explore statistical methods, calculators, and clinical trial analyses.
11. Record Summary
SANO is a randomized treatment trial evaluating active surveillance strategies in oesophageal cancer. The registry identifies overall survival as the primary endpoint and describes a randomized parallel-group design with 776 participants. The current ClinicalTrials.gov record does not contain posted statistical analyses or outcome results, so interpretation focuses on the planned endpoint framework and the statistical principles used for evaluating randomized survival studies.